Group 1 - The core point of the news is that Yangguang Nuohuo's stock price has dropped by 5.05%, currently trading at 69.15 yuan per share, with a total market capitalization of 7.745 billion yuan [1] - Yangguang Nuohuo is primarily engaged in the development of generic drugs, consistency evaluation, and innovative drug development, with 99.91% of its revenue coming from CRO services [1] - The company was established on March 9, 2009, and went public on June 21, 2021, located in Changping District, Beijing [1] Group 2 - According to data, the fund "Guangda Baodexin Health Youjia Mixed A" holds a significant position in Yangguang Nuohuo, having reduced its holdings by 83,700 shares in the fourth quarter, now holding 343,900 shares, which represents 2.8% of the fund's net value [2] - The fund has a total scale of 761 million yuan and has achieved a return of 5.95% this year, ranking 4476 out of 9003 in its category [2] - The fund manager, Xu Xiaojie, has been in position for 10 years and 260 days, with the best fund return during this period being 203.27% [3]